EU regulator backs use of Novo’s Wegovy for obesity-related heart disease – Reuters

by
  1. EU regulator backs use of Novo’s Wegovy for obesity-related heart diseaseReuters
  2. Novo Nordisk’s Wegovy receives EU support for the treatment of obesity-related heart failureThe Wall Street Journal
  3. Combination of semaglutide and mineralocorticoids may improve CKDMedscape
  4. Ozempic slows kidney disease, reduces risk of death in type 2 diabetesdiaTribe Foundation
  5. Novo Nordisk A/S: Wegovy® recommended for label update by European regulators to reduce heart failure symptoms and improve physical functionYahoo Finance

Leave a Comment